Patients with idiopathic pulmonary fibrosis (IPF) in Canada face challenges in equal access to quality healthcare services at the…
Articles by Alice Melão, MSc
Roche has acquired Promedior, a biotechnology company, and its full portfolio of molecules to possibly treat fibrotic diseases. The portfolio…
Treatment with the approved therapy Esbriet (pirfenidone), marketed by Genentech, helps preserve lung function in people with…
Fast weight loss in people with idiopathic pulmonary fibrosis (IPF), even after lung transplant, is linked with worse prognosis, and…
A Japanese agency has cleared MediciNova’s request for a patent covering the use of its orally available candidates MN-001…
Blade Therapeutics will expand its pipeline in the field of fibrotic diseases with the acquisition of Atxco and its…
Processa Pharmaceuticals will explore and further develop the anti-fibrotic, anti-inflammatory compound HT-100 as a potential treatment for rare…
At-home use of wearable physical activity trackers and portable spirometry devices may offer a feasible way of evaluating people…
Mutations in two genes, S100A3 and S100A13, were found to be linked to an atypical, early onset form of pulmonary fibrosis (PF)…
A patient with idiopathic pulmonary fibrosis (IPF), enrolled in the ZEPHYRUS Phase 3 clinical study, has been dosed with…